Shanghai Asieris Pharma dosed the first European patient in a global Phase III trial of its photodynamic drug-device combination product for cervical lesions. Cevira® is being developed as a novel non-surgical treatment for cervical high-grade squamous intraepithelial lesions. The drug-containing device contains a photosensitizer that activates the active ingredients via a specific wavelength of light. Asieris, which develops novel treatments for genitourinary tumors, in-licensed global rights to Cevira® from Photocure of Oslo in a $73 million agreement. More details.... Stock Symbol: (OSE: PHO) Share this with colleagues: // //